Untargeted 1H-NMR metabolomics in CSF: Toward a diagnostic biomarker for motor neuron disease

Neurology

Volumn 82, Issue 13, 2014, Pages 1167-1174

  Blasco, Hélène ^a,b,c   Nadal Desbarats, Lydie ^a,b   Pradat, Pierre François ^d   Gordon, Paul H ^d   Antar, Catherine ^a,b,c   Veyrat Durebex, Charlotte ^a,b   Moreau, Caroline ^e   Devos, David ^e   Mavel, Sylvie ^a,b   Emond, Patrick ^a,b,c   Andres, Christian R ^a,b,c   Corcia, Philippe ^a,b,f  

^a CHRU de Tours   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOISOVALERIC ACID; BIOLOGICAL MARKER; GLUCOSE; HISTIDINE; ISOBUTYRIC ACID; ISOLEUCINE; ISOVALERIC ACID; PHENYLALANINE; THREONINE; TYROSINE; VALINE;

ADULT; AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSIS RELATED GROUP; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LONGITUDINAL STUDY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOME; METABOLOMICS; MOTOR NEURON DISEASE; PATHOPHYSIOLOGY; POSTPOLIOMYELITIS SYNDROME; PREDICTIVE VALUE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SPASTIC PARAPLEGIA;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; MOTOR NEURON DISEASE;

EID: 84898728770     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000274     Document Type: Article

References (40)

1. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 2005;76:1046-1057.
2. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 2012;8:108-117.
3. Carra S, Crippa V, Rusmini P, et al. Alteration of protein folding and degradation in motor neuron diseases: implications and protective functions of small heat shock proteins. Prog Neurobiol 2012;97:83-100.
4. Gordon PH, Salachas F, Lacomblez L, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis 2013;12: 81-90.
5. Williams TL. Motor neurone disease: diagnostic pitfalls. Clin Med 2013;13:97-100.
6. Mitchell RM, Freeman WM, Randazzo WT, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009;72:14-19.
7. Sussmuth SD, Brettschneider J, Ludolph AC, Tumani H. Biochemical markers in CSF of ALS patients. Curr Med Chem 2008;15:1788-1801.
8. Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 2008;8:479-494.
9. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009;35:165-176.
10. Pradat PF, Dib M. Biomarkers in amyotrophic lateral sclerosis: facts and future horizons. Mol Diagn Ther 2009;13: 115-125.
11. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One 2011;6:e17947.
12. Wuolikainen A, Hedenstrom M, Moritz T, Marklund SL, Antti H, Andersen PM. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph Lateral Scler 2009;10:229-236.
13. Wuolikainen A, Andersen PM, Moritz T, Marklund SL, Antti H. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol Genet Metab 2012;105:472-478.
14. Blasco H, Corcia P, Moreau C, et al. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One 2010;5:e13223.
15. Blasco H, Corcia P, Pradat PF, et al. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J Proteome Res 2013;12:3746-3754.
16. Kumar A, Bala L, Kalita J, et al. Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta 2010;411:563-567.
17. Ala-Korpela M. Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool. Expert Rev Mol Diagn 2007;7:761-773.
18. Mandal R, Guo AC, Chaudhary KK, et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med 2012;4:38.
19. Bowser R, Lacomis D. Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve 2009;40:753-762.
20. Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012;13:1-10.
21. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
22. Wishart DS, Lewis MJ, Morrissey JA, et al. The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci 2008;871:164-173.
23. Ganesalingam J, Bowser R. The application of biomarkers in clinical trials for motor neuron disease. Biomark Med 2010;4:281-297.
24. Rozen S, Cudkowicz ME, Bogdanov M, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005;1:101-108.
25. Lawton KA, Cudkowicz ME, Brown MV, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler 2012;13:110-118.
26. Duggan GE, Hittel DS, Sensen CW,Weljie AM, Vogel HJ, Shearer J. Metabolomic response to exercise training in lean and diet-induced obese mice. J Appl Physiol 2011;110: 1311-1318.
27. Jung JY, Lee HS, Kang DG, et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke 2011;42: 1282-1288.
28. O'Sullivan A, Willoughby RE, Mishchuk D, et al. Metabolomics of cerebrospinal fluid from humans treated for rabies. J Proteome Res 2013;12:481-490.
29. Calabrese V, Lodi R, Tonon C, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 2005;233:145-162.
30. Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease: the integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis 2011;2011:276393.
31. Hipkiss AR. Could carnosine or related structures suppress Alzheimer's disease? J Alzheimers Dis 2007;11:229-240.
32. Ignacio S, Moore DH, Smith AP, Lee NM. Effect of neuroprotective drugs on gene expression in G93A/SOD1 mice. Ann NY Acad Sci 2005;1053:121-136.
33. Bellia F, Vecchio G, Cuzzocrea S, Calabrese V, Rizzarelli E. Neuroprotective features of carnosine in oxidative driven diseases. Mol Aspects Med 2011;32: 258-266.
34. Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. J Nutr 2001;131:846S-850S.
35. Hutson SM, Fenstermacher D, Mahar C. Role of mitochondrial transamination in branched chain amino acid metabolism. J Biol Chem 1988;263:3618-3625.
36. Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr 2006;136:207S-211S.
37. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002;193:73-78.
38. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
39. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10: 113-117.
40. Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001;74:328-334.